Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxime Dougados

Showing results (451-460 of 600) with videos related to

Pageof 60
Sort By:
Annals of the Rheumatic Diseases|August 1, 2019
Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohortsAnne Boel, Anna Molto, Désirée van der Heijde, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 24, 2014
Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trialJérémie Sellam, Sandrine Marion-Thore, Florent Dumont, et al.
BMJ (Clinical Research Ed.)|January 26, 2019
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort studyJacques-Eric Gottenberg, Jacques Morel, Elodie Perrodeau, et al.
Annals of the Rheumatic Diseases|October 1, 2016
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD studyMaxime Dougados, Désirée van der Heijde, Ying-Chou Chen, et al.
The Journal of Rheumatology|October 15, 2024
Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE StudiesVictoria Navarro-Compán, Martin Rudwaleit, Maureen Dubreuil, et al.
RMD Open|November 28, 2017
Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registryCynthia Nourisson, Martin Soubrier, Aurélien Mulliez, et al.
Rheumatology (Oxford, England)|May 7, 2021
Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohortBernard Combe, Nathalie Rincheval, Francis Berenbaum, et al.
The New England Journal of Medicine|November 14, 2003
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4IgJoel M Kremer, Rene Westhovens, Marc Leon, et al.
Annals of the Rheumatic Diseases|March 16, 2007
Research in hand osteoarthritis: time for reappraisal and demand for new strategies. An opinion paperMargreet Kloppenburg, Tanja Stamm, Iain Watt, et al.
Joint Bone Spine|July 30, 2017
Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA projectClementina López-Medina, Yolanda Jiménez-Gómez, Anna Moltó, et al.
Pageof 60

Showing results (451-460 of 600) with videos related to

Sort By:
Pageof 60
Annals of the Rheumatic Diseases|August 1, 2019
Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohortsAnne Boel, Anna Molto, Désirée van der Heijde, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 24, 2014
Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trialJérémie Sellam, Sandrine Marion-Thore, Florent Dumont, et al.
BMJ (Clinical Research Ed.)|January 26, 2019
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort studyJacques-Eric Gottenberg, Jacques Morel, Elodie Perrodeau, et al.
Annals of the Rheumatic Diseases|October 1, 2016
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD studyMaxime Dougados, Désirée van der Heijde, Ying-Chou Chen, et al.
The Journal of Rheumatology|October 15, 2024
Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE StudiesVictoria Navarro-Compán, Martin Rudwaleit, Maureen Dubreuil, et al.
RMD Open|November 28, 2017
Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registryCynthia Nourisson, Martin Soubrier, Aurélien Mulliez, et al.
Rheumatology (Oxford, England)|May 7, 2021
Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohortBernard Combe, Nathalie Rincheval, Francis Berenbaum, et al.
The New England Journal of Medicine|November 14, 2003
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4IgJoel M Kremer, Rene Westhovens, Marc Leon, et al.
Annals of the Rheumatic Diseases|March 16, 2007
Research in hand osteoarthritis: time for reappraisal and demand for new strategies. An opinion paperMargreet Kloppenburg, Tanja Stamm, Iain Watt, et al.
Joint Bone Spine|July 30, 2017
Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA projectClementina López-Medina, Yolanda Jiménez-Gómez, Anna Moltó, et al.
Pageof 60